Effect of Saptanga Guggul Along with Standard Treatment in Patients with Type 2 Diabetes Mellitus

A Randomized Controlled Trial to Evaluate the Efficacy and Safety of Saptanga Guggulu as an Adjunct to Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/07/113692

Enrollment

Registered

2026-07-08

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age group: between 30 years to 60 years. 2) Gender: Male and Female both will be included. 3) A known Diabetic on treatment 4) Fasting Blood Sugar: more than or equal to 126mg per dl and less than or equal to 250mg per dl Post Prandial Blood Sugar: more than 140mg per dl and less than 300mg per dl 5) Patient having HbA1C more than and equal to 10

Exclusion criteria

Exclusion criteria: 1) IDDM, Acromegaly, Cushing s syndrome and pancreatic disorder. 2) Pregnant and lactating mothers. 3) Patients with K/C/O Nephropathy, Neuropathy and Retinopathy. 4) Patients with gastrointestinal diseases, Liver diseases, tumours, cardio vascular disease, acute myocardial infarction, immune-compromised disease (HIV).

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of Saptanga Guggul 500 mg twice a day as an add on effect in management of Madhumeha with special reference to Diabetes mellitus type 2 for 90 daysTimepoint: Day 0,30,90	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Sachinkumar Sahebrao Patil

MAMs Sumatibhai shah ayurved mahavidyalaya Maalwadi Hadapsar Pune

drsachinkumarpatil@yahoo.com9822603608

Outcome results